Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Hydroxocobalamin may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
FOR This medicine contains hydroxocobalamin which is a form of Vitamin B 12. Vitamin B12 contains cobalt. Hydroxocobalamin is given for:
Cobalin-H Injection contains sodium Cobalin-H Injection contains less than 1mmol sodium (23 mg) per 1ml that is to say essentially 'sodium-free'.
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Cobalin-H Injection will be given to you by injection into a muscle. The dose depends on your individual needs and responses to treatment. Your blood levels of Vitamin B 12 and folic acid are likely to be monitored both before and during treatment. If you have doubts about the treatment or want more information about your medicine or the monitoring procedure, do ask the doctor or nurse. The recommended dose is Adults and Children Initial dose: This varies between 250 microgram and 1000 microgram given daily or on alternative days. The actual dosage depends on your specific illness and your response to treatment. Maintenance dose: Your doctor will check your condition regularly. When he/she feels that your health has improved sufficiently, your dose of Cobalin-H Injection will be reduced to 1mg every 2-3 months or as required. If you use more Cobalin-H Injection than you should: Being given more than the intended dose of hydroxocobalamin is unlikely to cause a problem requiring treatment. Tell the doctor if you are experiencing any side effects or think you may be reacting badly so that he/she can give appropriate treatment. If you have already left the medical premises, contact your nearest hospital, doctor or nurse. If you forget to take Cobalin-H injection: It is unlikely that you will miss a dose as your doctor or nurse will be giving it to you. However, it is important not to have a double dose if you have missed one. Ask your doctor or nurse when you should have the next dose. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 4. POSSIBLE SIDE EFFECTS Like all medicines this medicine can cause side effects, although not everybody gets them. Tell your doctor immediately if you experience any of the following symptoms after you have been given the injection. Although they are very rare, these symptoms can be serious.
not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
COBALIN-H INJECTION Keep this medicine out of the sight and reach of children. Store below 25oC and protect from light. The product should not be used if it is not a clear red liquid or if it contains visible particles. Do not use this medicine after the expiry date which is stated on the ampoule and carton after "EXP". The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Cobalin-H Injection contains The active substance is: hydroxocobalamin 1000 microgram/ml.
The other ingredients are: sodium dihydrogen orthophosphate, sodium chloride and Water for Injections with sodium hydroxide and/or hydrochloric acid as pH adjusters. The product is suitable for vegetarians and vegans. What Cobalin-H Injection looks like and contents of the pack The product is a clear red liquid, supplied in 5 clear glass vials. Each vial contains 1000 micrograms hydroxocobalamin. Marketing Authorisation Holder Amdipharm UK Limited, Dashwood House, 69 Old Broad Street, London, EC2M 1QS, United Kingdom (send all enquiries to this address). Manufacturer Mercury Pharmaceuticals Limited, Dashwood House, 69 Old Broad Street, London, EC2M 1QS, United Kingdom ®Cobalin-H injection is a registered trade mark PL 20072/0217 This leaflet was last revised in April 2024.
Cobalin-H 1000 microgram/ml Injection comes as injection containing 1000microgram/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Cobalin-H 1000 microgram/ml Injection is hydroxocobalamin.
This leaflet reproduces the patient information leaflet approved for Cobalin-H 1000 microgram/ml Injection, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Treatment of Addisonian pernicious anaemia.
Prophylaxis and treatment of other macrocytic anaemias due to vitamin B12 deficiency.
Treatment of tobacco amblyopia.
Treatment of Lieber's atrophy.
Posology
The following dosages are suitable for children and adults.
Addisonian pernicious anaemia and other macrocytic anaemias without neurological involvement:
Initially:
250 micrograms to 1000 micrograms intramuscularly on alternate days for one or two weeks then 250 micrograms weekly until blood count is normal.
Maintenance:
1000 micrograms every two or three months.
Addisonian pernicious anaemia and other macrocytic anaemias with neurological involvement:
Initially:
1000 micrograms on alternate days as long as improvement continues.
Maintenance:
1000 micrograms every two months.
Prophylaxis of macrocytic anaemias associated with vitamin B12 deficiency resulting from gastrectomy, ileal resection, certain ma/absorption states and vegetarianism:
1000 micrograms every two or three months.
Tobacco amblyopia and Leber's optic atrophy:
Initially:
1000 micrograms daily by intramuscular injection for two weeks then twice weekly as long as improvement is maintained.
Maintenance:
1000 micrograms every three months or as required.
Method of Administration
Intramuscular injection
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
It is advisable to confirm the diagnosis of Vitamin B12 deficiency before giving hydroxocobalamin; regular monitoring of the blood is recommended.
If megaloblastic anaemia fails to respond, folate metabolism should be investigated.
Doses in excess of 10 micrograms daily may produce a haematological response in patients with folate deficiency. Indiscriminate administration may mask the true diagnosis.
Cardiac arrhythmias secondary to hypokalaemia during initial therapy have been reported. Plasma potassium should therefore be monitored during this period.
Chloramphenicol
Parenteral chloramphenicol may attenuate the effect of hydroxocobalamin in anaemia.
Oral contraceptives
The serum concentration of hydroxocobalamin may be lowered.
The above interactions are unlikely to be of clinical significance but should be taken into account when performing assays for blood concentrations.
Vitamin B12 assays by microbiological techniques are invalidated by antimetabolites and most antibiotics.
Pregnancy
Hydroxocobalamin injection should not be used for the treatment of megaloblastic anaemia of pregnancy.
Breast-feeding
Hydroxocobalamin is secreted into breast milk but is unlikely to harm the infant.
Fertility
No data available
Not relevant.
The following adverse reactions are classified by system organ class and ranked under heading of frequency using the following convention:
Not known (cannot be estimated from the available data)
There are no modern clinical studies available that can be used to determine the frequency of undesirable effects. Therefore, all the undesirable effects listed are classed as “frequency Not known”.
The following effects have been reported and are listed below by body system:
System organ class
Frequency
Undesirable effects
Blood and lymphatic system disorders
Not Known
Reactive thrombocytosis can occur during the first weeks of use in megaloblastic anaemia.
Immune system disorders
Not Known
Hypersensitivity reactions including rash; itching; exanthema. Antibodies to hydroxocobalamin-transcobalamin II complex have developed during hydroxocobalamin therapy.
Anaphylaxis
Metabolism and nutrition disorders
Not Known
Initial hypokalaemia
Nervous system disorders
Not Known
Headache, paraesthesia, tremor.
Cardiac disorders
Not Known
Arrhythmias secondary to hypokalaemia.
Gastrointestinal disorders
Not Known
Nausea, vomiting, diarrhoea.
General disorders and administration site conditions
Not Known
Fever, chills, hot flushes; dizziness; malaise; pain; Injection site reactions including injection site pain, injection site erythema, injection site pruritus, injection site` induration, and injection site swelling.
Skin and subcutaneous tissue disorders
Not known
Acneiform and bullous eruptions
Renal and urinary disorders
Not Known
Chromaturia
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website : www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Treatment is unlikely to be needed in case of overdose.
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Cobalin-H 1000 microgram/ml Injection. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.